Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted with AS03A, in adults aged 18 years and above

Next Previous
Search
Trial Profile

A phase III, open, non-randomized, trial to evaluate the immunogenicity and safety of a two-dose schedule of the A/California/7/2009 (H1N1)v-like candidate vaccine manufactured in Dresden adjuvanted with AS03A, in adults aged 18 years and above

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Influenza A virus vaccine-H1N1 (Primary)
  • Indications Influenza A virus H1N1 subtype
  • Focus Pharmacodynamics
  • Acronyms FLU D-PAN H1N1-022
  • Sponsors GlaxoSmithKline; GSK

    • Most Recent Events

    • 15 Mar 2012 Official title amended as reported by EudraCT.
    • 19 May 2010 Actual patient number (312) added as reported by ClinicalTrials.gov.
    • 19 May 2010 Actual end date (Apr 2010) added as reported by ClinicalTrials.gov.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top